Literature DB >> 6333204

Epidemiology of parkinsonism: incidence, classification, and mortality.

A H Rajput, K P Offord, C M Beard, L T Kurland.   

Abstract

An epidemiological study of parkinsonism over a 13-year period (1967 through 1979) is presented, updating previous reports on incidence and trend in the population of Rochester, Minnesota. The overall average annual incidence of parkinsonism per 100,000 population was 20.5, adjusted to the 1970 total United States population, which is virtually unchanged from previous observations. Incidences calculated for each calendar year (1967 through 1979) revealed no remarkable change following the 1976 swine flu vaccination program. There was no sex difference and the peak incidence occurred between ages 75 and 84 years. Idiopathic Parkinson's disease was the most common variant (86%), followed by drug-induced parkinsonism (7%). There were no new cases of postencephalitic parkinsonism diagnosed during the study period. Relative frequency of other types of Parkinson's disease as identified by practicing neurologists is presented. For each case two age- and sex-matched controls were selected from the Rochester population. The survival rates in the controls were comparable to the general population of the west north central region of the United States. The mortalities in the patients were significantly higher (p = 0.001) than the controls and were unchanged from previous rates reported from the same community. In the 69 (50%) patients treated with levodopa, the mortality was comparable to that in controls. The favorable outcome in these cases is attributed to bias resulting from selection of healthier patients for treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6333204     DOI: 10.1002/ana.410160303

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  49 in total

1.  The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years.

Authors:  M A Hely; J G Morris; R Traficante; W G Reid; D J O'Sullivan; P M Williamson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

Review 2.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.

Authors:  R C Dodel; M Singer; R Köhne-Volland; T Szucs; B Rathay; E Scholz; W H Oertel
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

Review 4.  Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.

Authors:  Judith Dams; Bernhard Bornschein; Jens Peter Reese; Annette Conrads-Frank; Wolfgang H Oertel; Uwe Siebert; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

Review 5.  Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both?

Authors:  Rachel Saunders-Pullman
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

6.  Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques.

Authors:  Mark J C Nuijten; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Risk factors for Parkinson's disease may differ in men and women: an exploratory study.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Walter A Rocca
Journal:  Horm Behav       Date:  2012-06-08       Impact factor: 3.587

8.  Estimated life expectancy of Parkinson's patients compared with the UK population.

Authors:  Lianna S Ishihara; Anne Cheesbrough; Carol Brayne; Anette Schrag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-30       Impact factor: 10.154

Review 9.  Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Authors:  Carlos Estevez-Fraga; Paul Zeun; Jose Luis López-Sendón Moreno
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

10.  Neuroticism and extraversion in association with quality of life in patients with Parkinson's disease.

Authors:  Tatiana Dubayova; Iveta Nagyova; Eva Havlikova; Jaroslav Rosenberger; Zuzana Gdovinova; Berrie Middel; Jitse P van Dijk; Johan W Groothoff
Journal:  Qual Life Res       Date:  2008-11-07       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.